INVO Fertility Share Price

NAYA Biosciences, Inc. formerly INVO Bioscience, Inc. operates the fertility business, as well as its focus to the development of clinical-stage assets in oncology and autoimmune diseases. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. It offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.